Market News

TDOC Takes a Big Hit after Forecast Disappoints

Shares of Teladoc Health (NASDAQ:TDOC) fell in after-hours trading after the company reported earnings for its fourth quarter of Fiscal Year 2022. Earnings per share came in at a loss of $0.23, which beat analysts’ consensus estimate of a loss of $0.25 per share. Sales increased by 15.1% year-over-year, with revenue hitting $637.7 million. This beat analysts’ expectations of $633.37 million.

Teladoc Health saw revenue from access fees climb, ultimately hitting $553.7 million. That was up 16%, and other revenue sources saw similar gains. Other revenue was up to $84 million, a 10% increase. Teladoc’s percentage of revenue from the U.S. market, meanwhile, was up 15%, ultimately hitting $554.4 million. In addition, its international share reached $83.3 million, a 17% increase.

Looking forward, management now expects revenue for Q1 2023 to be in the range of $610 million to $625 million. EPS is expected to be in the range of a loss of $0.55 – $0.45. For reference, analysts were expecting $648.72 million in revenue and a loss of $0.43 in EPS.

Overall, Wall Street has a consensus price target of $32.18 on Teladoc with three Buys and nine Holds assigned, as indicated by the graphic above.


Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More